Dr. James Pinkerton is a Research Associate in the Respiratory Pharmacology group within the National Heart & Lung Institute.
James completed his PhD at the University of Newcastle, Australia in 2018, where he was focused on elucidating the mechanisms associated with severe, steroid-resistant asthma. During this time he established a novel high fat diet-induced model of steroid-resistant asthma to help understand the mechanisms driving this unique asthmatic endotype.
James' currently works with the Imperial College AstraZeneca site team and which is focused on investigating novel therapeutic targets in respiratory models of disease for potential treatment in asthma, COPD, IPF and other severe respiratory conditions.
et al., Inflammasomes in the lung, Molecular Immunology, ISSN:0161-5890
et al., 2017, Role for NLRP3 Inflammasome-mediated, IL-1 beta-Dependent Responses in Severe, Steroid-Resistant Asthma, American Journal of Respiratory and Critical Care Medicine, Vol:196, ISSN:1073-449X, Pages:283-297
et al., 2019, IL-5/IL-13 drive NLRP3 inflammasome-mediated, steroid-resistant AHR in a model of obesity-associated asthma, ERS International Congress 2019 abstracts, European Respiratory Society
et al., 2016, NLRP3 inflammasome-mediated, IL-1 beta-dependent inflammatory responses drive steroid-resistant asthma, EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN:0903-1936
et al., 2016, Investigating antioxidant therapy for steroid-resistant asthma, ERS International Congress 2016 abstracts, European Respiratory Society